Compare Quest Diagnostics Inc (DGX) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Palo Alto Networks Inc — how do they compare? Quest Diagnostics Inc trades at $204.68 (market cap $22.80B), while Palo Alto Networks Inc trades at $355.93 (market cap $287.61B). The key difference: Palo Alto Networks Inc is far larger — about 12.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| DGX | PANW | |
|---|---|---|
Market Cap | $22.80B | $287.61B |
Sector | Health | Technology |
52-Week High | $216.02 | $357.53 |
52-Week Low | $166.42 | $141.67 |
Enterprise Value | $28.82B | $286.57B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Palo Alto Networks (PANW) trades at $330.30, up 1.35% with a bullish technical outlook and strong earnings beats. The stock shows robust revenue growth to $9.22B in 2025 and a net income margin of 7.95%, though valuation ratios like P/E of 287.22 remain elevated. Recent news highlights cybersecurity sector tailwinds from AI-driven threats and IBM's client shifts, fueling positive sentiment.
Outlook is positive with 74% analyst buy ratings and a $336.65 consensus target, but high valuations and integration costs pose risks. Revenue growth and platformization strategy support upside, while competition and macroeconomic pressures require monitoring for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
